{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-025553","form_type":"8-K/A","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2022-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.588259+00:00","generated_at":"2026-06-23T07:15:43.588932+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bioventus files CartiHeal audited financials: 2021 net loss $10.2M, zero revenue","bullets":["CartiHeal had $0 revenue in 2021; net loss $10.2M; accumulated deficit $67.7M.","R&D expenses $7.8M; cash and equivalents $4.9M at Dec 31, 2021.","Acquisition closed July 12, 2022 for ~$315M upfront plus up to $135M in sales milestones.","Unaudited pro forma combined financials reflect acquisition for six months ended July 2, 2022 and FY 2021.","CartiHeal's Agili-C implant received FDA PMA in March 2022; pre-launch inventory provision of $642K reversed."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-025553","json":"https://secwatch.observer/filing/0001628280-22-025553.json","markdown":"https://secwatch.observer/filing/0001628280-22-025553.md","text":"https://secwatch.observer/filing/0001628280-22-025553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022025553/0001628280-22-025553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022025553/bvs-20220712.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:15:43.588932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}